|
gptkbp:instanceOf
|
gptkb:drug
cyclin-dependent kinase inhibitor
|
|
gptkbp:administeredBy
|
oral
|
|
gptkbp:approvalYear
|
2015
|
|
gptkbp:approvedBy
|
gptkb:FDA
gptkb:EMA
|
|
gptkbp:ATCCode
|
L01EF01
|
|
gptkbp:brand
|
gptkb:Ibrance
|
|
gptkbp:CASNumber
|
gptkb:571190-30-2
|
|
gptkbp:chemicalClass
|
pyridopyrimidine
|
|
gptkbp:color
|
white to yellow powder
|
|
gptkbp:combines
|
gptkb:fulvestrant
gptkb:letrozole
|
|
gptkbp:contraindication
|
hypersensitivity to palbociclib
|
|
gptkbp:developedBy
|
gptkb:Pfizer
|
|
gptkbp:discoveredBy
|
gptkb:Pfizer
|
|
gptkbp:eliminationHalfLife
|
29 hours
|
|
gptkbp:excretion
|
urine
feces
|
|
gptkbp:hasMolecularFormula
|
C24H29N7O2
|
|
gptkbp:hasSMILES
|
CC1=CC(=NC(=N1)N2CCN(CC2)C3=NC4=C(C=CC(=C4N3)C)C(=O)NC5=CC=CC=C5)C(=O)N
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Palbociclib
|
|
gptkbp:indication
|
HR-positive, HER2-negative advanced or metastatic breast cancer
|
|
gptkbp:interactsWith
|
CYP3A inducers
CYP3A inhibitors
|
|
gptkbp:KEGGID
|
D09913
|
|
gptkbp:lactationWarning
|
not recommended during breastfeeding
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:mechanismOfAction
|
inhibits cell cycle progression
|
|
gptkbp:metabolism
|
liver
|
|
gptkbp:patent
|
gptkb:Pfizer
|
|
gptkbp:patentExpired
|
2023 (US)
|
|
gptkbp:pregnancyCategory
|
D (US)
|
|
gptkbp:pregnancyWarning
|
may cause fetal harm
|
|
gptkbp:proteinBinding
|
85%
|
|
gptkbp:PubChem_CID
|
gptkb:CHEMBL1899636
5330286
DB09073
|
|
gptkbp:routeOfAdministration
|
oral
|
|
gptkbp:sideEffect
|
nausea
fatigue
alopecia
neutropenia
leukopenia
|
|
gptkbp:solubility
|
slightly soluble in water
|
|
gptkbp:target
|
gptkb:CDK4
gptkb:CDK6
|
|
gptkbp:UNII
|
8N3DW7272P
|
|
gptkbp:usedFor
|
gptkb:cancer
|
|
gptkbp:bfsParent
|
gptkb:Cdk4
gptkb:Serine/threonine-protein_kinase_CDK4
|
|
gptkbp:bfsLayer
|
8
|